-
Abstract Number: 2356
Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US
-
Abstract Number: 2357
Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
-
Abstract Number: 2358
Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis
-
Abstract Number: 2359
A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries
-
Abstract Number: 2360
Patient Selection and Treatment Outcomes Using Preliminary Data-driven Definition versus the Established ASAS Definition of a Positive MRI of the Sacroiliac Joint in axSpA: Post-hoc Analysis from COAST-X
-
Abstract Number: 2361
Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
-
Abstract Number: 2362
Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
-
Abstract Number: 2363
“How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
-
Abstract Number: 2364
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
-
Abstract Number: 2365
Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
-
Abstract Number: 2366
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
-
Abstract Number: 2367
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
-
Abstract Number: 2368
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
-
Abstract Number: 2369
Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
-
Abstract Number: 2370
Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
- « Previous Page
- 1
- …
- 157
- 158
- 159
- 160
- 161
- …
- 181
- Next Page »